Professor of Clinical Cardiology Michiel Rienstra specializes on atrial fibrillation and heart failure. In 2009, he received a NWO Rubicon grant to pursue a post-doctoral position in population genetics and epidemiology at Harvard Medical School, Massachusetts General Hospital, and the Framingham Heart Study. In this video Dr. Rienstra speaks about Digoxin Evaluation in Chronic Heart Failure.
Brief Synopsis: Digoxin is the oldest and cheapest FDA-approved medication for heart failure (HF). The DIG trial, a large digoxin trial conducted in the early 1990s, found a considerable reduction in HF hospitalizations but no effect on mortality. According to a post-hoc study of the DIG trial, decreased digoxin serum concentrations may reduce not just HF hospitalizations but also mortality in chronic HF patients. A prospective, randomized, placebo-controlled trial is needed to confirm these retrospective findings and to establish digoxin's current position in the therapy of HF. As a result, the researchers want to see if low-dose digoxin, with serum concentrations of 0.5-0.9ng/mL, is useful in HF patients with low or mid-range ejection fractions (LVEF 50%).
The ACC's Sandra J. Lewis Cardiovascular Women's Leadership Institute will support the unique needs of mid-career women as they continue to sustain and grow their leadership skills. Part of the ACC's Campaign for the Future, the Institute will further the College's Strategic Goals to foster a diverse pipeline of leaders within the profession and the ACC itself. "For many women, 15 to 20 years into their career, changes in responsibilities serve as an opportunity to reassess, reimagine and reinvent their professional lives," says Sandra J. Lewis, MD, FACC, whose transformational gift to the Campaign for the Future is making the Institute possible. "While this stage may serve as a professional renaissance for many, it is also a stage with opportunities for unique guidance and targeted leadership development to successfully transition forward 'to the next'.” Read more: http://bit.ly/2KefKk1#ACCFuture#ACCWIC
Non-communicable diseases are Mexico’s biggest killers, and people living in rural areas are most at risk – due to a lack of medical technology and health care workers with the right training. Watch a video to learn how an online academy is helping doctors all over the country give their communities the support they need.
Get more information on the NCD Academy or download the app at ncdacademy.acc.org.
This video was produced for the American College of Cardiology, in partnership with NCD Alliance, World Heart Federation, and Viatris Inc., by BBC StoryWorks, the commercial content division of BBC Global News.
John Gordon Harold, MD, MACC, ACC past president and chair of ACC’s Campaign for the Future, announces the public launch of the ACC's Campaign for the Future – a Mission-based philanthropic effort to empower future cardiovascular leaders, researchers, and clinicians; build a diverse and inclusive profession; and foster innovation and grow transformational global programs aimed at optimizing patient care and improving outcomes. According to Harold, “The Campaign for the Future is an important opportunity for ACC members worldwide to not only help shape the future of our profession but also build on the legacy of those cardiovascular giants who have come before.” Get involved at https://www.ACC.org/Future
ACC President Athena Poppas, MD, FACC, reflects on 2020 and shares her gratitude for how the global cardiovascular profession has come together to fight COVID-19, to stand against racism and violence, to promote diversity and inclusion in our workforce, and to address disparities in the health care system. “Together we have risen to every occasion in 2020 and together we will come out on the other side stronger and better prepared for future challenges,” she said. “I have never been prouder to be a part of the ACC and the larger cardiovascular community.” https://bit.ly/3m20ZOU
ACC President Athena Poppas, MD, FACC, discusses how "the ACC's commitment to optimizing global care and outcomes is now more important than ever" as the burden of cardiovascular disease is growing worldwide and will require coordinated efforts across borders, agency, NGOs, and more. Global prevention initiatives are a cost-effective and proven means to reducing cardiovascular mortality. The ACC is proud to work with partners like the World Health Organization, World Heart Federation, NDC Alliance, and others, as well as our U.S. and International Chapters and global cardiovascular societies on a number of prevention activities, including our newly launched ACC #NCDAcademy. Learn more at https://www.ACC.org/GlobalHub.